Enzymatica AB
Enzymatica AB (publ), a life science company, develops and sells medical devices for infection-related diseases. The company's product includes ColdZyme, a mouth spray that protects against the upper respiratory viruses that can cause cold and flu symptoms. It also provides enzyme formulations for skin care. The company was incorporated in 2007 and is headquartered in Lund, Sweden.
Market Cap & Net Worth: Enzymatica AB (EN9)
Enzymatica AB (F:EN9) has a market capitalization of $1.75K (€1.70K) as of March 19, 2026. Listed on the F stock exchange, this Germany-based company holds position #47470 globally and #7949 in its home market, demonstrating a 11.78% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Enzymatica AB's stock price €0.18 by its total outstanding shares 9693 (9.69K).
Enzymatica AB Market Cap History: 2026 to 2026
Enzymatica AB's market capitalization history from 2026 to 2026. Data shows growth from $1.75K to $1.75K (0.00% CAGR).
Enzymatica AB Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Enzymatica AB's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of EN9 by Market Capitalization
Companies near Enzymatica AB in the global market cap rankings as of March 19, 2026.
Key companies related to Enzymatica AB by market ranking:
- Zoetis Inc (NYSE:ZTS): Ranked #422 globally with a market cap of $51.61 Billion USD.
- Haleon plc (NYSE:HLN): Ranked #432 globally with a market cap of $49.87 Billion USD.
- Takeda Pharmaceutical Co. Ltd. (PINK:TKPHF): Ranked #452 globally with a market cap of $47.47 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #719 globally with a market cap of $28.19 Billion USD ( CN¥206.84 Billion CNY).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #422 | Zoetis Inc | NYSE:ZTS | $51.61 Billion | $117.35 |
| #432 | Haleon plc | NYSE:HLN | $49.87 Billion | $10.31 |
| #452 | Takeda Pharmaceutical Co. Ltd. | PINK:TKPHF | $47.47 Billion | $30.07 |
| #719 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $28.19 Billion | CN¥55.11 |
Enzymatica AB Historical Marketcap From 2026 to 2026
Between 2026 and today, Enzymatica AB's market cap moved from $1.75K to $ 1.75K, with a yearly change of 0.00%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €1.75K | -- |
End of Day Market Cap According to Different Sources
On Mar 19th, 2026 the market cap of Enzymatica AB was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.75K USD |
| MoneyControl | $1.75K USD |
| MarketWatch | $1.75K USD |
| marketcap.company | $1.75K USD |
| Reuters | $1.75K USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.